Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2009, p. 2129-2132, Vol. 53, No. 5
0066-4804/09/$08.00+0 doi:10.1128/AAC.01598-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Roche Palo Alto LLC, 3431 Hillview Ave., Palo Alto, California 94304
Received 2 December 2008/ Returned for modification 16 January 2009/ Accepted 25 February 2009
In vitro, telaprevir selects subtype-specific resistance pathways for hepatitis C virus GT-1a and GT-1b, as described to have occurred in patients. In GT-1a, the HCV-796 resistance mutation C316Y has low replication capacity (7%) that can be compensated for by the emergence of the mutation L392F or M414T, resulting in an increase in replication levels of
10-fold.
Published ahead of print on 9 March 2009.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»